United Therapeutics (UTHR) CEO sells 9,500 shares under 10b5-1 plan
Rhea-AI Filing Summary
UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options for common stock at an exercise price of $135.42 per share and acquired 9,500 common shares on August 25, 2026. The same day, those 9,500 indirectly held shares were sold in multiple open-market transactions at weighted average prices between $515.46 and $520.52 per share. After the option exercise, a family trust held 65,910 stock options, and separately, Rothblatt held 40,513 common shares directly and 166 shares indirectly through a spouse. These option exercises and related sales were made under a Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring March 15, 2027, or December 31, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 9,500 shares ($3.63M approx. pre-tax spread)
Exercise and Sale
13 txns
Insider
ROTHBLATT MARTINE A
Role
Chairperson & CEO
Sold
9,500 shs ($4.92M)
Approx. gross sale proceeds
$4.92M
Approx. exercise cost
$1.29M
Approx. pre-tax spread
$3.63M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F1, F12 | 9,500 | $0.00 | $0.00 |
| Exercise | Common Stock F1, F2 | 9,500 | $135.42 | $1.29M |
| Sale | Common Stock F1, F3, F2 | 2,029 | $516.1187 | $1.05M |
| Sale | Common Stock F1, F4, F2 | 2,332 | $516.9461 | $1.21M |
| Sale | Common Stock F1, F5, F2 | 2,004 | $518.0829 | $1.04M |
| Sale | Common Stock F1, F6, F2 | 2,387 | $518.7999 | $1.24M |
| Sale | Common Stock F1, F7, F2 | 668 | $519.9056 | $347K |
| Sale | Common Stock F1, F8, F2 | 80 | $520.495 | $42K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock F9 | -- | -- | -- |
| holding | Common Stock F10 | -- | -- | -- |
| holding | Common Stock F11 | -- | -- | -- |
Holdings After Transaction:
Stock Option — 65,910 shares (Indirect, by Trust);
Common Stock — 628,049 shares (Indirect, by Trust);
Common Stock — 40,513 shares (Direct);
Common Stock — 166 shares (Indirect, by Spouse)
Footnotes (12)
- F1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
- F10. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F11. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F12. Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
- F2. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F3. This transaction was executed in multiple trades at prices ranging from $515.46 to $516.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $516.46 to $517.405. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $517.46 to $518.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $518.46 to $519.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $519.46 to $520.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $520.47 to $520.52. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
Key Figures
Options exercised: 9,500 stock options
Exercise price: $135.42 per share
Shares sold: 9,500 shares
+5 more
8 metrics
Options exercised
9,500 stock options
Exercised on August 25, 2026 by a family trust
Exercise price
$135.42 per share
Exercise price of stock options into UNITED THERAPEUTICS common stock
Shares sold
9,500 shares
Total UNITED THERAPEUTICS common shares sold on August 25, 2026
Sale price range
$515.46–$520.52 per share
Weighted average price ranges for multiple sale tranches
Options held after exercise
65,910 stock options
Remaining derivative position in a family trust following the transaction
Direct common shares
40,513 shares
Common stock held directly by Martine A. Rothblatt after reported transactions
Spouse-held shares
166 shares
Common stock held indirectly through spouse
10b5-1 plan size
1,734,410 stock options
Maximum options to be exercised under the Rule 10b5-1 trading plan
Key Terms
Rule 10b5-1 trading plan, weighted average price, family trusts, investment power, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This exercise of stock options and sale ... was pursuant to a pre-arranged 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
family trusts financial
"Shares held in family trusts as to which the Reporting Person shares investment power"
investment power financial
"as to which the Reporting Person's spouse shares investment power"
stock options financial
"This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
FAQ
What insider transaction did UTHR CEO Martine Rothblatt report on August 25, 2026?
On August 25, 2026, Martine A. Rothblatt exercised 9,500 stock options for UNITED THERAPEUTICS Corp (UTHR) common stock at $135.42 per share and the resulting 9,500 shares were sold in multiple open-market trades on the same date.
How many UNITED THERAPEUTICS stock options did the family trust hold after the reported exercise?
After the August 25, 2026 exercise, a family trust associated with Martine A. Rothblatt held 65,910 stock options on UNITED THERAPEUTICS Corp common stock, according to the reported post-transaction derivative holdings.
Was Martine Rothblatt’s UTHR trading done under a Rule 10b5-1 plan?
Yes. The option exercise and sale of UNITED THERAPEUTICS (UTHR) shares were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of exercising 1,734,410 options or December 31, 2026.
What is the size and duration of Martine Rothblatt’s current UTHR 10b5-1 plan?
The Rule 10b5-1 plan covers up to 1,734,410 stock options that expire on March 15, 2027 and will continue until the earlier of those options being exercised or December 31, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
